C-Path Consortium Adds Gene Editing and Advanced Imaging Leaders to Accelerate Alpha-1 Research

Posted on Mon/1/DecemberMon/24/November by Roxan Olivas

Beam Therapeutics and the Open Source Imaging Consortium join C-Path’s CPA-1 program, bringing gene editing innovation and global lung imaging data resources to advance new therapies for alpha-1 antitrypsin deficiency.Continue reading→

C-Path Announces New Name and Strategic Direction for its PRO Consortium

Posted on Tue/25/NovemberThu/20/November by Roxan Olivas

Newly renamed Patient-Centered Evidence Consortium expands focus to advance the science and impact of patient-centered evidence in drug development.Continue reading→

C-Path’s International Neonatal Consortium Launches Groundbreaking Neonatal Lab Values GUI Tool to Standardize Reference Ranges in Neonatal Trials

Posted on Fri/21/NovemberThu/20/November by Roxan Olivas

TUCSON, Ariz., November 2025 — Critical Path Institute’s® (C-Path) International Neonatal Consortium (INC) today announced the public launch of its Neonatal Laboratory Values Graphical User Interface (Neo-LV) Tool, a first-of-its-kind platform designed to harmonize and standardize laboratory reference ranges in neonatal research and clinical trials.Continue reading→

FDA Qualifies C-Path Biomarker GLDH to Detect Liver Injury in Clinical Trials

Posted on Thu/20/NovemberThu/20/November by Roxan Olivas

C-Path’s Predictive Safety Testing Consortium led effort to qualify liver-specific biomarker to improve safety monitoring in those with muscle disease.Continue reading→

C-Path’s Disease Modeling Coalition Begins Global Pediatric IBD Work from European Hub

Posted on Thu/16/OctoberThu/16/October by Roxan Olivas

AMSTERDAM, October 16, 2025 — Critical Path Institute® (C-Path) today announced the official launch of the Critical Path Disease Modeling Coalition (CP-DMC) on pediatric inflammatory bowel disease (pIBD).Continue reading→

Critical Path Institute to be Honored with Reagan-Udall Foundation Innovation Award

Posted on Tue/14/OctoberTue/14/October by Roxan Olivas

Award honors regulatory science advances with measurable public health impact; ceremony December 9, 2025, Willard InterContinental, Washington, D.C.Continue reading→

C-Path Names Colin Hill to Board of Directors

Posted on Tue/30/SeptemberTue/30/September by Roxan Olivas

TUCSON, Ariz., Sept. 30, 2025 — Critical Path Institute^® (C-Path) today announced the election of Colin Hill, M.S., to its Board of Directors. Hill brings deep experience at the intersection of artificial intelligence, drug development, and translational acceleration. The appointment will further strengthen C-Path’s Board of Directors’ commitment to provide optimal strategic support to the organization’s growth in advancing drug development through collaboration.Continue reading→

C-Path Concludes 2025 Global Impact Conference with Progress Across Rare Diseases, Neurology and Pediatrics

Posted on Thu/11/SeptemberThu/11/September by Roxan Olivas

Global regulators, industry leaders, scientists, and patient advocates set near-term commitments on early interception, trial modernization, and patient-first evidence.Continue reading→

C-Path’s Translational Therapeutics Accelerator Marks Record Year with Seven BRIDGe Awards Advancing Potential Therapies Across Cancer, Infectious Disease, Neurology and Immunology

Posted on Thu/4/SeptemberThu/4/September by Roxan Olivas

Program launched in 2022 has grown into a global pipeline partner for academic teams, awarding approximately $2.48 million in 2025 to projects in the U.S., Europe and AustraliaContinue reading→